Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | ATM | Q13315 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31611950 | 1.00 | MEN1 (0.64) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL16070584 | 1.00 | MEN1 (0.64) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL29419010 | 0.89 | KMT2A (0.80) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL28595722 | 0.89 | KMT2A (0.80) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL29389283 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL30195162 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL461986 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL461985 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL16070464 | 0.83 | NPC1 (0.53) | MEN1KMT2ANPC1RAB9AATM | |
| Hydrochloric Acid SCHEMBL8045709 | 0.81 | MEN1 (0.73) | MEN1KMT2ANPC1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111004215-B | 2, 4-substituted pyrimidine derivatives, preparation method thereof and application thereof in preparing antitumor drugs | 华北理工大学 | 2022-08-09 | — | — | CN | claimed |
| CN-111004215-A | 2, 4-substituted pyrimidine derivatives, preparation method thereof and application thereof in preparing antitumor drugs | 华北理工大学 | 2020-04-14 | — | — | CN | claimed |
| CN-110172037-A | A kind of pyridine structure contained styrylpyridinium compound, preparation method and its application for preparing anti-tumor drug | 华北理工大学 | 2019-08-27 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2023-08-29 | — | — | US | disclosed |
| CN-111004215-B | 2, 4-substituted pyrimidine derivatives, preparation method thereof and application thereof in preparing antitumor drugs | 华北理工大学 | 2022-08-09 | — | — | CN | disclosed |
| US-20210300871-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-09-30 | — | — | US | disclosed |
| CN-111304778-A | Method for preparing two-photon fluorescent skin-color spandex | 华峰重庆氨纶有限公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-111004215-A | 2, 4-substituted pyrimidine derivatives, preparation method thereof and application thereof in preparing antitumor drugs | 华北理工大学 | 2020-04-14 | — | — | CN | disclosed |
| CN-110172037-A | A kind of pyridine structure contained styrylpyridinium compound, preparation method and its application for preparing anti-tumor drug | 华北理工大学 | 2019-08-27 | — | — | CN | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1648401-A2 | COMPOSITION COMPRISING AT LEAST ONE SUBSTITUTED 2- 2-(4-AMINOPHENYL)ETHENYL|-1-PYRIDINIUM DERIVATIVE, METHOD FOR TREATING KERATIN FIBRES USING THE ABOVE, DEVICE AND USE | L'OREAL (FR) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050191253-A1 | Composition comprising at least one substituted 2-[2-(4-amino phenyl)ethenyl]-1-pyridinium derivative, process for treating keratin fibres using it, device and use thereof | L'OREAL S.A. (FR) | 2005-09-01 | — | — | US | disclosed |
| WO-2005004822-A3 | COMPOSITION COMPRISING AT LEAST ONE SUBSTITUTED 2-[2-(4-AMINOPHENYL)ETHENYL]-1-PYRIDINIUM DERIVATIVE, METHOD FOR TREATING KERATIN FIBRES USING THE ABOVE, DEVICE AND USE | OREAL (FR) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005004822-A2 | COMPOSITION COMPRISING AT LEAST ONE SUBSTITUTED 2-[2-(4-AMINOPHENYL)ETHENYL]-1-PYRIDINIUM DERIVATIVE, METHOD FOR TREATING KERATIN FIBRES USING THE ABOVE, DEVICE AND USE | L'OREAL (FR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005004822-A2 | COMPOSITION COMPRISING AT LEAST ONE SUBSTITUTED 2-[2-(4-AMINOPHENYL)ETHENYL]-1-PYRIDINIUM DERIVATIVE, METHOD FOR TREATING KERATIN FIBRES USING THE ABOVE, DEVICE AND USE | L'OREAL (FR) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300871-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | HAVCR2, CBR3, C1R | MEN1 3433/4885KMT2A 2616/4885NPC1 1358/4885 |
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | HAVCR2, CBR3, C1R | MEN1 3433/4885KMT2A 2616/4885NPC1 1358/4885 |
| US-20050191253-A1 | Composition comprising at least one substituted 2-[2-(4-amino phenyl)ethenyl]-1-pyridinium derivative, process for treating keratin fibres using it, device and use thereof | KRT18, TPM4, KLK5 | MEN1 3862/4885KMT2A 625/4885NPC1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.